Company intelligence / Profile preview
Endeavor BioMedicines
San Diego, California, United Statesendeavorbiomedicines.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Endeavor BioMedicines’ lead candidate ENV-101, a Hedgehog pathway inhibitor, has entered a Phase 2b trial for idiopathic pulmonary fibrosis and has shown potential to improve lung function and reverse key measures of lung fibrosis. Their second candidate ENV-501, an anti-HER3 ADC for solid tumors, is advancing toward clinical proof-of-concept studies
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Small molecule inhibitor (ENV-101)Antibody-drug conjugate (ADC) (ENV-501)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships disclosed as of May 2025; recent financing led by AyurMaya/Matrix Capital Management with participation from top-tier life sciences investors.
Beyond the preview
Go deeper on Endeavor BioMedicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endeavor BioMedicines.